Author:
Friedman Mark T.,West Kamille A.,Bizargity Peyman,Annen Kyle,Gur H. Deniz,Hilbert Timothy
Publisher
Springer International Publishing
Reference9 articles.
1. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.
2. SOLIRIS®. Prescribing information. Boston, MA: Alexion Pharmaceuticals; 2020.
3. ULTOMIRIS®. Prescribing information. Boston, MA: Alexion Pharmaceuticals; 2020.
4. Wynick C, Britto J, Sawler D, Parker A, Karkhaneh M, Goodyear D, Sun HL. Validation of the PLASMIC score for predicting ADAMTS13 activity < 10% in patients admitted to hospitals in Alberta with suspected thrombotic thrombocytopenic purpura. Blood. 2019;134(Suppl 1):2379.
5. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(323):324.